RESEARCH TRIANGLE PARK, N.C., Nov. 7, 2010 /PRNewswire-FirstCall/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today reaffirmed its commitment to the dual development of CMX001 as a medical countermeasure against smallpox and as a broad-spectrum antiviral agent.  This statement follows notification from the Small Business Administration (SBA) that it has determined that SIGA Technologies, Inc. is not a small business, thus rendering SIGA ineligible for award of a government contract from the Biomedical Advanced Research and Development Authority (BARDA) that was designated as a small business set-aside.  

"Chimerix is deeply committed to developing and advancing safe, effective medicines that benefit public health.  We support the efforts of the Department of Health and Human Services to ensure that the government's requirement for smallpox therapeutics is met expeditiously and in accordance with Federal Acquisition Regulations," stated Kenneth I. Moch, President and Chief Executive Officer of Chimerix.  

"The most important advancement we have made in the clinical and preclinical development of our lead antiviral candidate, CMX001, is to establish its profile as a broad-spectrum therapeutic with the potential to treat a number of fatal diseases.  Our clinical experience with patients to date keeps us extremely motivated to see its development through registration and approval. Combined with its potential to address the smallpox threat, we feel CMX001 is well positioned to address the broadest definition of unmet medical need," said Wendy Painter, M.D., M.P.H., Chief Medical Officer of Chimerix.

CMX001 – An Antiviral with Broad-Spectrum Activity

CMX001 is in advanced development as a medical countermeasure for the treatment of smallpox.  CMX001 has demonstrated protection from mortality in animal models of human smallpox disease in multiple pr